Stocklytics Platform
Asset logo for symbol NBIX
Neurocrine Biosciences
NBIX83
$119.69arrow_drop_up0.53%$0.63
High Quality
High Growth
Asset logo for symbol NBIX
NBIX83

$119.69

arrow_drop_up0.53%

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•
•

Neurocrine Biosciences (NBIX) Stocklytics Forecast

Neurocrine Biosciences Inc (NBIX) is a biopharmaceutical company focused on discovering and developing innovative treatments for neurological and endocrine disorders. With a strong pipeline and multiple promising drug candidates, many investors are keen to know the future outlook for NBIX stock.
When it comes to predicting the future stock price of NBIX, there are several factors to consider. One approach is to analyze historical data and trends. By examining the company's financial performance, clinical trial results, and market conditions, analysts can make informed forecasts. However, it is important to note that past performance does not guarantee future results.
add Neurocrine Biosciences to watchlist

Keep an eye on Neurocrine Biosciences

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is the analyst price prediction for Neurocrine Biosciences (NBIX) stock?

Analysts have set a target price of $159.11 for Neurocrine Biosciences (NBIX), based on forecasts from 27 analysts. The predicted price range extends from a high of $216 to a low of $127. This represents a potential increase of up to 80.45% and a decrease of 6.1% from the current price of $119.7. These forecasts are as of 2023 Dec 13.
help

What are the analyst ratings for Neurocrine Biosciences (NBIX) stock?

Currently, there are no analyst ratings available for Neurocrine Biosciences (NBIX), possibly due to insufficient coverage or recent updates.
help

What is the AI price prediction for Neurocrine Biosciences (NBIX) stock?

At present, there is no AI or machine-learning-based price prediction available for Neurocrine Biosciences (NBIX) stock. The lack of a forecast could stem from various factors, such as inadequate data or the necessity for model recalibration.

Take Your Investments to a Whole New Level